Loading...

Hatim Husain

Title(s)Associate Clinical Professor, Medicine
SchoolHealth Sciences
Phone858-822-6135
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Johns Hopkins University, Baltimore, MDMedical Oncology
    University of Southern California, Los Angeles, CAInternal Medicine
    Northwestern University, Chicago, ILDoctor of Medicine

    Collapse Research 
    Collapse Research Activities and Funding

    Role Description: I am a lung cancer medical oncologist at UCSD Moores Cancer Center pursuing a translational career in cancer therapeutic strategies in solid tumor malignancies. My passion is be involved in early drug development and my goal is to develop a translational laboratory for biomarker validation and drug testing in in vitro and in in vivo models that can form the basis for early phase clinical trials. I work very closely to characterize technology development in the circulating tumor DNA space and applications about its utility. Recent work has also involved in understanding mechanisms of resistance to anti-EGFR directed therapies and further understanding the mechanisms of immunogenic cell death in cancer cells.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse Faculty Mentoring
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ma F, Guan Y, Yi Z, Chang L, Li Q, Chen S, Zhu W, Guan X, Li C, Qian H, Xia X, Yang L, Zhang J, Husain H, Liao Z, Futreal A, Huang J, Yi X, Xu B. Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer. Int J Cancer. 2019 Jun 26. PMID: 31241775.
      View in: PubMed
    2. Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, Jensen SØ, Medina JE, Hruban C, White JR, Palsgrove DN, Niknafs N, Anagnostou V, Forde P, Naidoo J, Marrone K, Brahmer J, Woodward BD, Husain H, van Rooijen KL, Ørntoft MW, Madsen AH, van de Velde CJH, Verheij M, Cats A, Punt CJA, Vink GR, van Grieken NCT, Koopman M, Fijneman RJA, Johansen JS, Nielsen HJ, Meijer GA, Andersen CL, Scharpf RB, Velculescu VE. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019 Jun; 570(7761):385-389. PMID: 31142840.
      View in: PubMed
    3. Wang Y, Zhao C, Chang L, Jia R, Liu R, Zhang Y, Gao X, Li J, Chen R, Xia X, Bulbul A, Husain H, Guan Y, Yi X, Xu J. Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine. 2019 May; 43:261-269. PMID: 31031019.
      View in: PubMed
    4. Murtuza A, Bulbul A, Shen JP, Keshavarzian P, Woodward BD, Lopez-Diaz FJ, Lippman SM, Husain H. Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer. Cancer Res. 2019 Feb 15; 79(4):689-698. PMID: 30718357.
      View in: PubMed
    5. Phallen J, Leal A, Woodward BD, Forde PM, Naidoo J, Marrone KA, Brahmer JR, Fiksel J, Medina JE, Cristiano S, Palsgrove DN, Gocke CD, Bruhm DC, Keshavarzian P, Adleff V, Weihe E, Anagnostou V, Scharpf RB, Velculescu VE, Husain H. Early Noninvasive Detection of Response to Targeted Therapy in Non-Small Cell Lung Cancer. Cancer Res. 2019 Mar 15; 79(6):1204-1213. PMID: 30573519.
      View in: PubMed
    6. Marcoux N, Gettinger SN, O'Kane G, Arbour KC, Neal JW, Husain H, Evans TL, Brahmer JR, Muzikansky A, Bonomi PD, Del Prete S, Wurtz A, Farago AF, Dias-Santagata D, Mino-Kenudson M, Reckamp KL, Yu HA, Wakelee HA, Shepherd FA, Piotrowska Z, Sequist LV. EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes. J Clin Oncol. 2019 Feb 01; 37(4):278-285. PMID: 30550363.
      View in: PubMed
    7. Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol. 2018 11 01; 4(11):1527-1534. PMID: 30073261.
      View in: PubMed
    8. Bulbul A, Forde PM, Murtuza A, Woodward B, Yang H, Bastian I, Ferguson PK, Lopez-Diaz F, Ettinger DS, Husain H. Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer. Oncology (Williston Park). 2018 04 15; 32(4):156-63. PMID: 29684234.
      View in: PubMed
    9. Bulbul A, Husain H. First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option? Front Oncol. 2018; 8:94. PMID: 29755953.
      View in: PubMed
    10. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N, Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, Banks KC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD, Mack PC, Gandara DR, Husain H, Doebele RC, Riess JW, Diehn M, Swanton C, Bivona TG. Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec; 49(12):1693-1704. PMID: 29106415.
      View in: PubMed
    11. Bulbul A, Fahy BN, Xiu J, Rashad S, Mustafa A, Husain H, Hayes-Jordan A. Desmoplastic Small Round Blue Cell Tumor: A Review of Treatment and Potential Therapeutic Genomic Alterations. Sarcoma. 2017; 2017:1278268. PMID: 29225486.
      View in: PubMed
    12. Husain H, Velculescu VE. Cancer DNA in the Circulation: The Liquid Biopsy. JAMA. 2017 10 03; 318(13):1272-1274. PMID: 28973237.
      View in: PubMed
    13. Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA. Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. Oncotarget. 2017 Oct 27; 8(52):89848-89866. PMID: 29163793.
      View in: PubMed
    14. Phallen J, Sausen M, Adleff V, Leal A, Hruban C, White J, Anagnostou V, Fiksel J, Cristiano S, Papp E, Speir S, Reinert T, Orntoft MW, Woodward BD, Murphy D, Parpart-Li S, Riley D, Nesselbush M, Sengamalay N, Georgiadis A, Li QK, Madsen MR, Mortensen FV, Huiskens J, Punt C, van Grieken N, Fijneman R, Meijer G, Husain H, Scharpf RB, Diaz LA, Jones S, Angiuoli S, Ørntoft T, Nielsen HJ, Andersen CL, Velculescu VE. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017 Aug 16; 9(403). PMID: 28814544.
      View in: PubMed
    15. Yeung KT, More S, Woodward B, Velculescu V, Husain H. Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer. Mol Diagn Ther. 2017 08; 21(4):375-384. PMID: 28337711.
      View in: PubMed
    16. Schwaederlé MC, Patel SP, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017 Sep 01; 23(17):5101-5111. PMID: 28539465.
      View in: PubMed
    17. Husain H, Nykin D, Bui N, Quan D, Gomez G, Woodward B, Venkatapathy S, Duttagupta R, Fung E, Lippman SM, Kurzrock R. Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology. Mol Cancer Ther. 2017 05; 16(5):948-955. PMID: 28468865.
      View in: PubMed
    18. Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen E, Lippman SM, Kurzrock R. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clin Cancer Res. 2017 Aug 15; 23(16):4716-4723. PMID: 28420725.
      View in: PubMed
    19. Park SJ, More S, Murtuza A, Woodward BD, Husain H. New Targets in Non-Small Cell Lung Cancer. Hematol Oncol Clin North Am. 2017 02; 31(1):113-129. PMID: 27912827.
      View in: PubMed
    20. Husain H, Scur M, Murtuza A, Bui N, Woodward B, Kurzrock R. Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer. Mol Cancer Ther. 2017 02; 16(2):265-272. PMID: 28159915.
      View in: PubMed
    21. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel SP, Harismendy O, Ikeda M, Parker BA, Kurzrock R. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. PMID: 27185373.
      View in: PubMed
    22. Bui N, Woodward B, Johnson A, Husain H. Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer. Curr Treat Options Oncol. 2016 May; 17(5):25. PMID: 27085533.
      View in: PubMed
    23. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Banks KC, Lanman RB, Talasaz A, Parker BA, Kurzrock R. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. Oncotarget. 2016 Mar 01; 7(9):9707-17. PMID: 26848768.
      View in: PubMed
    24. Seguin L, Kato S, Franovic A, Camargo MF, Lesperance J, Elliott KC, Yebra M, Mielgo A, Lowy AM, Husain H, Cascone T, Diao L, Wang J, Wistuba II, Heymach JV, Lippman SM, Desgrosellier JS, Anand S, Weis SM, Cheresh DA. An integrin ß3-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol. 2014 May; 16(5):457-68. PMID: 24747441.
      View in: PubMed
    25. Husain H, Psyrri A, Markovic A, Rampias T, Pectasides E, Wang H, Slebos R, Yarbrough WG, Burtness B, Chung CH. Nuclear epidermal growth factor receptor and p16 expression in head and neck squamous cell carcinoma. Laryngoscope. 2012 Dec; 122(12):2762-8. PMID: 23086695.
      View in: PubMed
    26. Husain H, Savage W, Grossman SA, Ye X, Burger PC, Everett A, Bettegowda C, Diaz LA, Blair C, Romans KE, Holdhoff M. Pre- and post-operative plasma glial fibrillary acidic protein levels in patients with newly diagnosed gliomas. J Neurooncol. 2012 Aug; 109(1):123-7. PMID: 22492246.
      View in: PubMed
    27. Husain H, Rudin CM. ALK-targeted therapy for lung cancer: ready for prime time. Oncology (Williston Park). 2011 Jun; 25(7):597-601. PMID: 21888258.
      View in: PubMed
    28. Husain H, Hann C, Hales R. Radiotherapy in small-cell lung cancer. Oncology (Williston Park). 2010 Oct; 24(11):1047, 1049. PMID: 21155457.
      View in: PubMed
    29. Lurje G, Hendifar AE, Schultheis AM, Pohl A, Husain H, Yang D, Manegold PC, Ning Y, Zhang W, Lenz HJ. Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. Pharmacogenet Genomics. 2009 Feb; 19(2):95-102. PMID: 18987561.
      View in: PubMed
    30. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res. 2008 Dec 01; 14(23):7884-95. PMID: 19047118.
      View in: PubMed
    31. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. PMID: 18192902.
      View in: PubMed